These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 19337533)

  • 1. Safety and efficacy of cilostazol in the management of intermittent claudication.
    Chi YW; Lavie CJ; Milani RV; White CJ
    Vasc Health Risk Manag; 2008; 4(6):1197-203. PubMed ID: 19337533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol: a new drug in the treatment intermittent claudication.
    Kumar M; Bhattacharya V
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):181-5. PubMed ID: 18221117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
    Grouse JR; Allan MC; Elam MB
    J Clin Pharmacol; 2002 Dec; 42(12):1291-8. PubMed ID: 12463722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
    Smith JA
    Clin Cardiol; 2002 Mar; 25(3):91-4. PubMed ID: 11892686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The US experience with cilostazol in treating intermittent claudication.
    Hiatt WR
    Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilostazol: improving walking distance in patients with intermittent claudication.
    Collinson DJ; Donnelly R
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):503-9. PubMed ID: 15225110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol.
    Donnelly R
    Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S20-5. PubMed ID: 12180354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of peripheral arterial disease in the elderly: focus on cilostazol.
    Falconer TM; Eikelboom JW; Hankey GJ; Norman PE
    Clin Interv Aging; 2008; 3(1):17-23. PubMed ID: 18488875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapy for intermittent claudication.
    Rowlands TE; Donnelly R
    Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):314-21. PubMed ID: 17532651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.